Tevard Biosciences, Inc., a biotechnology company pioneering tRNA-based therapies, presented new preclinical data at the 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held from May 11-15 in Boston. The data demonstrate that the company's next-generation suppressor tRNAs (sup-tRNAs) restore full-length dystrophin protein and achieve wild-type levels of functional rescue in multiple mouse models of nonsense mutation-mediated Duchenne muscular dystrophy (DMD). Additionally, the company presented data showing that its novel sup-tRNAs provide durable rescue of full-length titin protein in a mouse model and functional rescue in human cardiomyocyte models of dilated cardiomyopathy caused by TTN truncations (DCM-TTNtv).
According to the announcement, Tevard's next-generation suppressor tRNAs achieve approximately 100% restoration of full-length dystrophin in DMD models and deliver durable full-length titin rescue in TTN-related cardiomyopathy. The company's compact tRNA architecture enables flexible AAV packaging, precise dose control, and broad applicability for pathogenic nonsense mutations across diverse unmet medical needs. These findings underscore the versatility of the suppressor tRNA platform and its ability to restore native protein expression in a cell-specific, durable manner.
The presented programs highlight the potential of Tevard's sup-tRNA technology to address genetic diseases caused by premature termination codons. By restoring endogenous, full-length protein expression, the platform offers a novel therapeutic approach for conditions such as Duchenne muscular dystrophy and dilated cardiomyopathy, which currently have limited treatment options. Tevard is advancing programs in muscular dystrophies, heart disease, and neurological disorders, leveraging its proprietary suppressor tRNA platform.
For more information about Tevard Biosciences and its research, visit www.tevard.com. The full announcement, including downloadable images and bios, is available here.
